EOLS

Evolus Inc

Add to Watchlist

Advanced Chart

11.570

+0.260(+2.300%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

11.730

Open

11.330

VWAP

11.52

Vol

561.78K

Mkt Cap

745.92M

Low

11.180

Amount

6.47M

EV/EBITDA(TTM)

Total Shares

62.61M

763.72M

EV/OCF(TTM)

P/S(TTM)

2.63

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

85.38M

+39.77%

-0.063

-65.3%

82.33M

+23.04%

-0.093

+47.91%

72.44M

+22.1%

-0.143

+30.62%

Estimates Revision

The market is revising Downward the revenue expectations for Evolus, Inc. (EOLS) for FY2025, with the revenue forecasts being adjusted by -0.28% over the past three months. During the same period, the stock price has changed by -18.58%.

Revenue Estimates for FY2025

Revise Downward

-0.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9100%

In Past 3 Month

Stock Price

Go Down

-18.58%

In Past 3 Month

7 Analyst Rating

109.94% Upside

Wall Street analysts forecast EOLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EOLS is 24.29 USD with a low forecast of 21.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

109.94% Upside

Current: 11.570

Low

21.00

Averages

24.29

High

27.00

109.94% Upside

Current: 11.570

Low

21.00

Averages

24.29

High

27.00

BTIG

Sam Eiber

Strong Buy

Initiates

$21

2025-04-17

Reason

BTIG

Sam Eiber

Price Target

$21

2025-04-17

Initiates

Strong Buy

Reason

BTIG analyst Sam Eiber initiated coverage of Evolus with a Buy rating and $21 price target. Evolus is a performance beauty company that operates in the cash-pay medical aesthetic market, the analyst tells investors in a research note. The firm says the company's "differentiated go-to-market strategy" as a non-therapeutic, cash-pay company allows it to bypass third-party payer reimbursement dynamics, enabling greater pricing flexibility and the ability to reinvest into provider practices through co-branded marketing initiatives. BTIG sees several paths for Evolus to achieve its goal of at least $700M in revenue and non-GAAP operating income margin of at least 20%.

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$27

2025-04-10

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$27

2025-04-10

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

$22

2025-04-09

Reason

Needham

Serge Belanger

Price Target

$22

2025-04-09

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

$22

2025-03-05

Reason

Needham

Serge Belanger

Price Target

$22

2025-03-05

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$27

2025-03-05

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$27

2025-03-05

Reiterates

Strong Buy

Reason

Barclays

Balaji Prasad

Buy

Maintains

$22 → $25

2025-03-05

Reason

Barclays

Balaji Prasad

Price Target

$22 → $25

2025-03-05

Maintains

Buy

Reason

Barclays analyst Balaji Prasad raised the firm's price target on Evolus to $25 from $22 and keeps an Overweight rating on the shares. The Evoylsse label includes weight-loss as a cause of facial wrinkles, which is a first and should enhance its GLP-1 related uptake, the analyst tells investors in a research note. The firm says this launch positions Evolus as a stronger competitor and aids in greater account penetration.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Evolus Inc (EOLS.O) is -98.35, compared to its 5-year average forward P/E of -57.98. For a more detailed relative valuation and DCF analysis to assess Evolus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-57.98

Current PE

-98.35

Overvalued PE

194.68

Undervalued PE

-310.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1481.18

Current EV/EBITDA

106.28

Overvalued EV/EBITDA

5138.61

Undervalued EV/EBITDA

-8100.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.87

Current PS

2.05

Overvalued PS

3.82

Undervalued PS

1.93